Skip to main content
SpringerLink
Log in

Sandostatin® and Gastroenteropancreatic Endocrine Tumors — Therapeutic Characteristics

  • Conference paper
Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors

Abstract

Although its existence had been suggested by earlier work, somatostatin was conclusively identified by Guillemin and associates in 1972 during a search for growth hormone-releasing factors in hypothalamic extracts. Growth hormone release-inhibitory activity was found to be due to a cyclic peptide named somatostatin or somatotropin release inhibitory factor (SRIF). Somatostatin was detected soon afterwards in the D-cells of the pancreatic islets [20] and in the D-cells of the stomach and small intestine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altimari A. F., Bhoopalam N., O’Dorisio T., Lange C. L., Sandberg L., Prinz R. A.: Use of somatostatin analogue (SMS 201–995) in the glucagonoma syndrome. Surgery 1986; 100:989–996

    PubMed  CAS  Google Scholar 

  2. Bloom S. R., Mortimer C. H., Thorner M. O., Hall R., Gomez-Pan A., Roy V. M., Russell A. C. G., Coy D. H., Kastin A. J., Schally A. V.: Inhibition of gastrin and gastric acid secretion by growth hormone release inhibiting hormone. Lancet 1974; 11:1106–1109

    Article  Google Scholar 

  3. Bloom S. R., Polak J. M.: Glucagonomas, VIPomas and somatostatinomas. Clin Endocrinol Metab 1980; 9:285–297

    Article  PubMed  CAS  Google Scholar 

  4. Boden G., Sivitz M. C., Owen O. E.: Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 1975; 190:163–165

    Article  PubMed  CAS  Google Scholar 

  5. Bonfils S., Ruszniewski P., Costil V., Lancournet H., Vatier J., Rene E., Mignon M.: Prolonged treatment of Zollinger-Ellison syndrome by long-acting somatostatin. Lancet 1986; 1:554–555

    Article  PubMed  CAS  Google Scholar 

  6. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77–79

    Article  PubMed  CAS  Google Scholar 

  7. Ch’ng J. L. C., Anderson J. V., Williams S. J., Carr D. H., Bloom S. R.: Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumors with long-acting somatostatin analogue. B Med J 1986; 292:981–982

    Article  CAS  Google Scholar 

  8. Clements D., Elias E.: Regression of metastatic VIPoma with somatostatin analogue SMS 201–995. Lancet 1985; 1:874–875

    Article  PubMed  CAS  Google Scholar 

  9. Comi R. J., Gesundheit N., Murray L., Gorden P., Weintraub B. D.: Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 1987; 317:12–17

    Article  PubMed  CAS  Google Scholar 

  10. Defeudis F. V., Moreau J.-P.: Studies on somatostatin analogues might lead to new therapies for certain types of cancer. Trends Pharmacol Sci 1986; 7:384–386

    Article  CAS  Google Scholar 

  11. Fuessl H. S., Domin J., Anderson J. V., Bloom S. R.: Chronic administration of the somatostatin analogue SMS 201–995 does not lead to endogenous antibody formation. Aliment Pharmacol Ther 1987; 1:45–50

    Article  PubMed  CAS  Google Scholar 

  12. Gonzalez-Barcena D., Rangel-Garcia N. E., Perez-Sanchez P. L., Gutierrez-Damperio C., Garcia-Carrasco F., Comaru-Schally A. M., Schally A. V.: Response to D-Trp-6-LH-RH in advanced adenocarcinoma of the pancreas. Lancet 1986; 2:154

    Article  PubMed  CAS  Google Scholar 

  13. Juby L. D., Burke D. A., Axon A. T. R.: Somatostatin analogue SMS 201–995 long-term therapy for VIPoma. Postgrad Med J 1987; 63:287–289

    Article  PubMed  CAS  Google Scholar 

  14. Koelz A., Kraenzlin M., Gyr K., Meier V., Bloom S. R., Heitz P., Stalder H.: Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma. Gastroenterology 1987; 92:527–531

    PubMed  CAS  Google Scholar 

  15. Koerker D. J., Ruch W., Chideckel E.: Somatostatin: Hypothalamic inhibitor of the endocrine pancreas. Science 1974; 184:484

    Article  Google Scholar 

  16. Kvols L. K., Moertel C. G., O’Connell M. J., Schutt A. J., Rubin J., Halin R. G.: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663–666

    Article  PubMed  CAS  Google Scholar 

  17. Kvols L. K., Buck M., Moertel C. G., Schutt A. J., Rubin J., O’Connell M. J., Hahn R. G.: Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201–995). Ann Intern Med 1987; 107:162–168

    PubMed  CAS  Google Scholar 

  18. Lembke B., Creutzfeldt W., Schleser S., Ebert R., Shaw C., Koop I.: Effect of the somatostatin analogue Sandostatin (SMS 201–995) on gastrointestinal, pancreatic and biliary function and hormone release in normal man. Digestion 1987; 36:103–124

    Google Scholar 

  19. Lightman S. L., Fox P., Dunne M.J.: The effect of SMS 201–995, a long-acting somatostatin analogue on anterior pituitary function in healthy male volunteers. In: Bloom S. R., Greenwood C. (eds) Proceedings of somatostatin 85. Scand J Gastroenterol 1986; 21 [Suppl 119]:84–95

    Google Scholar 

  20. Luft R., Efendic S., Hokfelt T., Johansson O., Arimura A.: Immunohistochemical evidence for the localization of somatostatin-like immunoreactivity in a cell population of the pancreatic islets. Med Biol 1974; 52:428–430

    PubMed  CAS  Google Scholar 

  21. McCumbee W. D., McCarty K. S. Jr, Lebowitz H. E.: Hormone responsiveness of a transplantable rat chondrosarcoma. II. Evidence for in vivo hormone dependence. Endocrinology 1980; 106:1930–1940

    Article  PubMed  CAS  Google Scholar 

  22. Marsh H. M., Martin J. K., Kvols L. K., Gracey D. R., Warner M. A., Warner M. E., Moertel C. G.: Carcinoid crisis during anaesthesia: Successful treatment with a somatostatin analogue. Anaesthesiology 1987; 66:89–91

    Article  CAS  Google Scholar 

  23. Maton P. N., O’Dorisio T. M., Brent A., Howe B. S., McArthur E., Howard J. M., Cherner J. A., Malarkey T. B., Collen M. J., Gardner J. D., Jensen R. T.: Effect of a long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera. N Engl J Med 1985; 312:17–21

    Article  PubMed  CAS  Google Scholar 

  24. Osei K., O’Dorisio T. M.: Malignant insulinoma: Effects of a somatostatin analogue (compound 201–995) on serum glucose, growth and gastroenteropancreatic hormones. Ann Intern Med 1985; 103:223–225

    PubMed  CAS  Google Scholar 

  25. Pless J., Bauer W., Briner U., Doepfner W., Marbach P., Maurer R., Petcher T. J., Reubi J. C., Vonderscher J.: Chemistry and pharmacology of SMS 201–995, a long-acting octapeptide analogue of somatostatin. In: Bloom S. R., Greenwood C. (eds) Proceedings of somatostatin 85. Scand J Gastroenterol 1986; 21 [Suppl 119]:54–64

    Google Scholar 

  26. Reichlin S.: Somatostatin. N Engl J Med 1983; 309:1459–1501 and 1556–1563

    Article  Google Scholar 

  27. Reubi J. C.: Somatostatin receptors as markers for endocrine tumors. JAMA 1987; 257:3277

    Article  PubMed  CAS  Google Scholar 

  28. Schlegel W., Raptis S., Harvery R. F., Oliver J. M., Pfeiffer E. F.: Inhibition of cholecystokinin-pancreozymin release by somatostatin. Lancet 1977; ii:166–167

    Article  Google Scholar 

  29. Shepherd J. J., Senator G. B.: Regression of liver metastases in a patient with gastrin-secreting tumor treated with SMS 201–995. Lancet 1986; ii:574

    Article  Google Scholar 

  30. Vinik A. I., Tsai S. T., Moattari A. R., Cheung P., Eckhauser F. E., Cho K.: Somatostatin analogue (SMS 201–995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 1986; 81 [Suppl 6 B]:23–40

    Article  PubMed  CAS  Google Scholar 

  31. Weil C.: Gastroenteropancreatic endocrine tumors. Klin Wochenschr 1985; 63:433–459

    Article  PubMed  CAS  Google Scholar 

  32. Von Werder K., Losa M., Muller O. A., Schweiberer L., Fahlbusch R., Del Pozo E.: Treatment of metastasising GRF-producing tumor with a long-acting somatostatin analogue. Lancet 1984; 11:282–283

    Article  Google Scholar 

  33. Williams G., Fuessl H., Kraenzlin M., Bloom S. R.: Postprandial effects of SMS 201–995 on gut hormones and glucose tolerance. In: Bloom S. R., Greenwood C. (eds) Proceedings of somatostatin 85. Scand J Gastroenterol 1986; 21 [Suppl 119]:73–83

    Google Scholar 

  34. Wood S. M., Kraenzlin M. E., Adrian T. E., Bloom S. R.: Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide responses. Gut 1985; 26:438–444

    Article  PubMed  CAS  Google Scholar 

  35. Wormann B., Kutz K., Ottenjann R.: Treatment of relapsing bleeding peptic ulcers with the somatostatin analogue SMS 201–995 in a patient with Zollinger-Ellison syndrome. Hepatogastroenterology 1985; 32:152–153

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health, AIDS Unit, London, UK

    M. J. Dunne

  2. Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey, USA

    R. Elton, P. Hofker & J. Shui

  3. Clinical Research Unit London (CRUL), Sandoz House, Feltham, UK

    T. Fletcher

Authors
  1. M. J. Dunne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Elton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Fletcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Hofker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Shui
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. College of Medicine, Department of Endocrinology, The Ohio State University, 410 West 10th Street, Columbus, Ohio, 43210, USA

    T. M. O’Dorisio M. D.

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer Verlag, Berlin Heidelberg

About this paper

Cite this paper

Dunne, M.J., Elton, R., Fletcher, T., Hofker, P., Shui, J. (1989). Sandostatin® and Gastroenteropancreatic Endocrine Tumors — Therapeutic Characteristics. In: O’Dorisio, T.M. (eds) Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61328-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61328-9_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64794-9

  • Online ISBN: 978-3-642-61328-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation